Sign In
Buy NVO
$47.41
-0.0100 (-0.0211%)
At Close: Jun 24, 2026
Novo Nordisk A/S – Share repurchase programme
07:02am, Monday, 30'th Sep 2024
Bagsværd, Denmark, 30 September 2024 – On 7 August 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Co
Success in This New Battleground Could Make Eli Lilly and Novo Nordisk Stock Absolutely Fly for Years
10:00am, Saturday, 28'th Sep 2024
Eli Lilly and Novo Nordisk are spending billions to find new cardiometabolic drugs. Both companies are interested in the possibilities of genetic medicines.
3 Stocks That Could Rise on European Bank Interest Rate Cuts
01:10pm, Friday, 27'th Sep 2024
U.S. stocks reacted positively following the Federal Open Market Committee's announcement in mid-September that it would lower interest rates by 50 basis points, wider than many analysts had anticipat
PFE vs. NVO: Which Stock Is the Better Value Option?
12:46pm, Friday, 27'th Sep 2024
Investors interested in stocks from the Large Cap Pharmaceuticals sector have probably already heard of Pfizer (PFE) and Novo Nordisk (NVO). But which of these two stocks presents investors with the b
Novo Nordisk Just Committed More Than $1.1 Billion to Make the Next Ozempic, but Is the Stock a Buy?
08:45am, Friday, 27'th Sep 2024
It's in Novo Nordisk's best interest to produce more winning cardiometabolic drugs. To that end, it's inking collaboration deals with multiple early-stage biotechs.
Novo Nordisk And Evotec Collaborate On Stem Cell-Based Therapy Development
10:33am, Thursday, 26'th Sep 2024
On Thursday, Evotec SE EVO entered a technology development partnership with Novo Nordisk A/S NVO in cell therapy.
Is It Worth Investing in Novo Nordisk (NVO) Based on Wall Street's Bullish Views?
10:32am, Thursday, 26'th Sep 2024
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often
Novo Nordisk's $600 Million Gambit Could Be a Game Changer for the Stock. Here's Why.
05:40am, Thursday, 26'th Sep 2024
Novo Nordisk is cutting a lot of deals with small biotechs. The latest deal seeks to develop gene-editing therapies, perhaps for obesity.
Evotec and Novo Nordisk forge technology development partnership
02:14am, Thursday, 26'th Sep 2024
German drug and development company Evotec has entered into a technology development partnership with Novo Nordisk to support clinical and commercial manufacturing of stem cell-based therapies, the co
Evotec and Novo Nordisk Enter into Technology Development Partnership to Support Next-Generation Cell Therapies
02:00am, Thursday, 26'th Sep 2024
Novo Nordisk will provide funding for technology development activities at Evotec to support clinical and commercial manufacturing of stem cell-based therapies HAMBURG, GERMANY / ACCESSWIRE / Septembe
Lose Weight With Novo Nordisk Drugs, Gain Money With Stock
05:47pm, Wednesday, 25'th Sep 2024
Some experts believe Novo Nordisk A/S NVO products not only help people lose weight and control diabetes, they can help treat the country's addiction crisis.
LLY, NVO & Mag 7: Stocks to Watch After Fed's Rate Cut
12:58pm, Wednesday, 25'th Sep 2024
Steven E. Orr says people are getting healthier, and the accessibility of weight loss drugs from companies like Eli Lilly (LLY) and Novo Nordisk (NVO) make them attractive for investors. However, he w
Novo Nordisk's diabetes drug Ozempic may lower the risk of opioid overdoses, study says
11:00am, Wednesday, 25'th Sep 2024
Novo Nordisk's blockbuster diabetes drug Ozempic may decrease the risk of opioid overdoses in certain patients, according to a new study. The results suggest semaglutide, the active ingredient in Ozem
Belltopper Gold Project Video
09:25am, Wednesday, 25'th Sep 2024
VANCOUVER, British Columbia, Sept. 25, 2024 (GLOBE NEWSWIRE) -- Novo Resources Corp. (Novo or the Company) (ASX: NVO) (TSX: NVO) (OTCQX: NSRPF) is pleased to provide a video update on the Company's hi
Novo Nordisk (NVO) Rises Higher Than Market: Key Facts
06:51pm, Tuesday, 24'th Sep 2024
Novo Nordisk (NVO) closed at $125.44 in the latest trading session, marking a +1.41% move from the prior day.
